STACKD Research is educational—not medical advice. Disclaimer
A peptide notebook for people who read the research first.
Profiles, evidence levels, and study notes—kept in the open, argued over in community. Educational research, not medical advice.
30 compounds profiledEvidence-codedCommunity open to read
The library
30 deep profiles prioritizing the names people actually search—including retatrutide—written for diligence, not hype.
An investigational triple agonist (GLP-1, GIP, and glucagon receptors) studied for obesity and metabolic disease. Currently the highest-profile name in the space—widely framed as the next-generation successor to tirzepatide, with heavy search interest among fitness audiences.
Fat loss · Metabolic
A GLP-1 receptor agonist (marketed as Ozempic, Wegovy, and Rybelsus) with robust clinical evidence for glycemic control and weight management. The molecule that mainstreamed this category and a reference point for understanding incretin-based approaches discussed in fitness communities.
Fat loss · Metabolic
A dual GIP/GLP-1 receptor agonist (marketed as Mounjaro and Zepbound) with extensive clinical data in type 2 diabetes and obesity. Frequently compared head-to-head with semaglutide in conversations about metabolic peptides and body recomposition.
Fat loss · Metabolic
The open bench
The community is a research bench, not a chat board. Every thread is a typed object—questions, claims, field notes—and claims have to declare how strong their evidence is and cite the work. Reading is open to everyone; posting takes a free account.
Latest on the bench
Combinations, lightly
Names like GLOW surface when goals match—as “commonly discussed together” notes that link to each peptide. No protocols, no stacks.
Research digest + Cycle
Get study roundups and early access when STACKD Cycle launches.
Research digest + STACKD Cycle early access. One signup, education only—unsubscribe anytime.
By joining you agree to receive research updates and Cycle early-access notes. Not medical advice.